Literature DB >> 21088872

The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.

Phylinda L S Chan1, Philippe Jacqmin, Marc Lavielle, Lynn McFadyen, Barry Weatherley.   

Abstract

Using simulated viral load data for a given maraviroc monotherapy study design, the feasibility of different algorithms to perform parameter estimation for a pharmacokinetic-pharmacodynamic-viral dynamics (PKPD-VD) model was assessed. The assessed algorithms are the first-order conditional estimation method with interaction (FOCEI) implemented in NONMEM VI and the SAEM algorithm implemented in MONOLIX version 2.4. Simulated data were also used to test if an effect compartment and/or a lag time could be distinguished to describe an observed delay in onset of viral inhibition using SAEM. The preferred model was then used to describe the observed maraviroc monotherapy plasma concentration and viral load data using SAEM. In this last step, three modelling approaches were compared; (i) sequential PKPD-VD with fixed individual Empirical Bayesian Estimates (EBE) for PK, (ii) sequential PKPD-VD with fixed population PK parameters and including concentrations, and (iii) simultaneous PKPD-VD. Using FOCEI, many convergence problems (56%) were experienced with fitting the sequential PKPD-VD model to the simulated data. For the sequential modelling approach, SAEM (with default settings) took less time to generate population and individual estimates including diagnostics than with FOCEI without diagnostics. For the given maraviroc monotherapy sampling design, it was difficult to separate the viral dynamics system delay from a pharmacokinetic distributional delay or delay due to receptor binding and subsequent cellular signalling. The preferred model included a viral load lag time without inter-individual variability. Parameter estimates from the SAEM analysis of observed data were comparable among the three modelling approaches. For the sequential methods, computation time is approximately 25% less when fixing individual EBE of PK parameters with omission of the concentration data compared with fixed population PK parameters and retention of concentration data in the PD-VD estimation step. Computation times were similar for the sequential method with fixed population PK parameters and the simultaneous PKPD-VD modelling approach. The current analysis demonstrated that the SAEM algorithm in MONOLIX is useful for fitting complex mechanistic models requiring multiple differential equations. The SAEM algorithm allowed simultaneous estimation of PKPD and viral dynamics parameters, as well as investigation of different model sub-components during the model building process. This was not possible with the FOCEI method (NONMEM version VI or below). SAEM provides a more feasible alternative to FOCEI when facing lengthy computation times and convergence problems with complex models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21088872      PMCID: PMC3020311          DOI: 10.1007/s10928-010-9175-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  25 in total

1.  Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells.

Authors:  G A Funk; M Fischer; B Joos; M Opravil; H F Günthard; B Ledergerber; S Bonhoeffer
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

2.  Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming.

Authors:  Lars Lindbom; Jakob Ribbing; E Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2004-08       Impact factor: 5.428

3.  Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheinerz
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

4.  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

5.  Nonlinear mixed effects models for repeated measures data.

Authors:  M L Lindstrom; D M Bates
Journal:  Biometrics       Date:  1990-09       Impact factor: 2.571

6.  Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling.

Authors:  Philippe Jacqmin; Lynn McFadyen; Janet R Wade
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-03-04       Impact factor: 2.745

Review 7.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982

Review 8.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

9.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

10.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

View more
  26 in total

1.  Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.

Authors:  Elodie L Plan; Alan Maloney; France Mentré; Mats O Karlsson; Julie Bertrand
Journal:  AAPS J       Date:  2012-04-14       Impact factor: 4.009

2.  Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers.

Authors:  Noureddine Hamitouche; Emmanuelle Comets; Mégane Ribot; Jean-Claude Alvarez; Eric Bellissant; Bruno Laviolle
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

Review 3.  Covariate pharmacokinetic model building in oncology and its potential clinical relevance.

Authors:  Markus Joerger
Journal:  AAPS J       Date:  2012-01-25       Impact factor: 4.009

4.  Model based design and analysis of phase II HIV-1 trials.

Authors:  Dinko Rekić; Daniel Röshammar; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-07-11       Impact factor: 2.745

5.  Explicit reformulations of the Lambert W-omega function for calculations of the solutions to one-compartment pharmacokinetic models with Michaelis-Menten elimination kinetics.

Authors:  Marko Goličnik
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-05-01       Impact factor: 2.441

6.  Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM.

Authors:  François Riglet; France Mentre; Christine Veyrat-Follet; Julie Bertrand
Journal:  AAPS J       Date:  2020-02-19       Impact factor: 4.009

Review 7.  Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy.

Authors:  Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

8.  From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.

Authors:  Jing Fang; Pravin R Jadhav
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-06-27       Impact factor: 2.745

9.  Population pharmacokinetics and haemodynamic effects of norepinephrine in hypotensive critically ill children.

Authors:  Mehdi Oualha; Jean-Marc Tréluyer; Fabrice Lesage; Laure de Saint Blanquat; Laurent Dupic; Philippe Hubert; Odile Spreux-Varoquaux; Saïk Urien
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

10.  Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial design.

Authors:  Yulia Vugmeyster; Cynthia Rohde; Mylene Perreault; Ruth E Gimeno; Pratap Singh
Journal:  MAbs       Date:  2013-03-25       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.